ClinicalTrials.gg
Sign In
Not yet recruitingNCT07755709Updated Aug 10, 2026

Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum

An observational study in Placenta Accreta, Third Trimester, sponsored by Sohag University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Primary Objective:

To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta). To evaluate the diagnostic accuracy of the novel Ultrasound Scoring System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).

Secondary Objective:

  • To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).

  • To assess the relationship between the novel ultrasound score and postoperative complications, such as:

    • Requirement for hysterectomy
    • Bladder or bowel injury
    • Blood transfusion requirement
    • ICU admission rates
  • To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.
Read the detailed description

Primary Objective:

  • To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta).
  • To evaluate the diagnostic accuracy of the novel Ultrasound Scoring
  • System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).

Secondary Objective:

  • To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).

  • To assess the relationship between the novel ultrasound score and postoperative complications, such as:

    • Requirement for hysterectomy
    • Bladder or bowel injury
    • Blood transfusion requirement
    • ICU admission rates
  • To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.
02

Conditions studied

  • Placenta Accreta, Third Trimester

Browse trials for

Keywords

  • placenta accreta
03

In context

Placenta Accreta

150 studies on the registry are indexed under Placenta Accreta; 40 are open to participants now.

This study's planned enrollment of 50 is below the median of 87 across 78 observational studies indexed under Placenta Accreta.

Browse Placenta Accreta studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women aged 18 to 45 years. Gestational age ≥28 weeks at the time of enrollment.

Diagnosed Placenta Previa with a history of:

One or more previous cesarean sections Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 to 45 years.
  • Gestational age ≥28 weeks at the time of enrollment.

  • Diagnosed Placenta Previa with a history of:

    • One or more previous cesarean sections
    • Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty).
  • Singleton pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Women with multiple pregnancies (twins, triplets, etc.).
  • Pregnancies complicated by acute medical conditions (e.g., heart failure, uncontrolled diabetes).
  • Prior history of Blood diseases. (other than those related to pregnancy).
  • Women who refuse to participate or withdraw consent during the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. degree of placental invasion and inability to conserve the uterus

    Need for Hysterectomy: Determined by the degree of placental invasion and inability to conserve the uterus \&Histopathogy confirmation. Bladder Injury: Recorded if any injury occurs during the procedure. Blood Transfusion Requirement: Amount of blood transfused intraoperatively. ICU Admission: Postoperative ICU admission requirement due to hemorrhage or other complications.

    Time frame: 1 week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jan 2027, 4 months later.

Of 34 observational studies under Placenta Accreta, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Aug 10, 2026
StartEst.
Aug 4, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07755709
Lead sponsor
Sohag University
Responsible party
Ahmed Adel Khalifa (Ahmed Adel Khalifa Mansour, Sohag University) — Principal investigator
First posted
Aug 10, 2026
Start date
Aug 4, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Ahmed Adel Khalifa, resident
Contact
ahmedarsnl@gmail.com
01096679590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Placenta Accreta →

Other studies from this sponsor

Sohag University →

Start the discussion